8-K Announcements
6Material company update
May 7, 2026·SEC
Material company update
Mar 30, 2026·SEC
Material company update
Feb 11, 2026·SEC
Neumora Therapeutics, Inc. Common Stock(NMRA)Earnings, Financials & Key Ratios
NMRA•NASDAQ
$1.61
Price updated Jun 27, 2026
AboutNeumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; and NMRA-266, which is in the phase 1 clinical trial for the treatment of schizophrenia and other neuropsychiatric disorders. In addition, its preclinical phase product includes NMRA-NMDA for the treatment of schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson's disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.Show more
- Revenue$0
- EBITDA-$241M+8.3%
- Net Income-$237M+2.8%
- EPS (Diluted)-1.45+5.2%
- ROE-121.21%-88.0%
NMRA Price & Volume
Neumora Therapeutics, Inc. Common Stock (NMRA) stock price & volume — 10-year historical chart
Loading chart...
Persistent Clinical Burn Challenges Neumora Liquidity Runway
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Mixed
Profitability:Negative
Financial Position:Vulnerable
Cash Flow:Burning
Primary Risk:Clinical hold liquidity crunch
"Neumora Therapeutics remains a high-risk, pre-revenue biotechnology firm entirely dependent on external capital to fund its precision psychiatry pipeline. The company faces significant valuation pressure following the clinical hold on its NMRA-266 program, which forces an increased reliance on the success of navacaprant. Investors should monitor the company's ability to manage its $50 million average quarterly net loss while navigating a tightening liquidity position as cash reserves have declined to $147.1 million as of 2026Q1."
Verdict Logic
the company's reliance on external financing is underscored by a rapid decline in cash reserves to $147.1 million and a cumulative retained earnings deficit of $1.2 billion, which warrants extreme caution regarding future dilution.
NMRA Growth Metrics
Neumora Therapeutics, Inc. Common Stock (NMRA) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM13.82%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM17.39%
Return on Capital
10 Years-64.15%
5 Years-66.85%
3 Years-73.6%
Last Year-108.22%
NMRA Recent Earnings
Neumora Therapeutics, Inc. Common Stock (NMRA) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 4/12 qtrs (36%)
Q2 2026Latest
May 7, 2026Metric
Actual
Est
EPS
$0.30+6.3%
$0.32
Rev
—
—
Q2 2026
Mar 16, 2026Metric
Actual
Est
EPS
$0.35-2.9%
$0.34
Rev
—
—
Q4 2025
Nov 6, 2025Metric
Actual
Est
EPS
$0.35-2.9%
$0.34
Rev
—
—
Q3 2025
Aug 6, 2025Metric
Actual
Est
EPS
$0.33+13.2%
$0.38
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 7, 2026 | $0.30vs $0.32+6.3% | — |
| Q2 2026 | Mar 16, 2026 | $0.35vs $0.34-2.9% | — |
| Q4 2025 | Nov 6, 2025 | $0.35vs $0.34-2.9% | — |
| Q3 2025 | Aug 6, 2025 | $0.33vs $0.38+13.2% | — |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Neumora Therapeutics, Inc. Common Stock (NMRA)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $1.62 | $299.23M | -1.11 | — | — | -121.21% | — | |
| $25.32 | $4.34B | 11.06 | 11.87% | 34.3% | 35.65% | — | |
| $23.57 | $1.74B | 7.14 | 18.52% | 118.91% | 47.59% | — | |
| $241.67 | $12.44B | -65.67 | 65.55% | -26.59% | -260.01% | — | |
| $327.79 | $9.47B | -24.32 | -100% | — | -43.02% | — | |
| $84.43 | $7B | 10.85 | 114.51% | -22.58% | — | — |
Compare NMRA vs Peers
Neumora Therapeutics, Inc. Common Stock (NMRA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
NMRA SEC Filings & Documents
Neumora Therapeutics, Inc. Common Stock (NMRA) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when NMRA posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
NMRA Frequently Asked Questions
Neumora Therapeutics, Inc. Common Stock (NMRA) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Is NMRA profitable?
Neumora Therapeutics, Inc. Common Stock (NMRA) reported a net loss of $222.4M for fiscal year 2025.
Dividend & Returns
What is NMRA's return on equity?
Neumora Therapeutics, Inc. Common Stock (NMRA) has a return on equity (ROE) of -121.2%. Negative ROE indicates the company is unprofitable.
What is Neumora Therapeutics, Inc. Common Stock's free cash flow?
Neumora Therapeutics, Inc. Common Stock (NMRA) had negative free cash flow of $193.4M in fiscal year 2025, likely due to heavy capital investments.